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Abstract
Congenital adrenal hyperplasia (CAH) is one of the most prevalent, and potentially 
severe, genetic inborn errors of steroid synthesis directly affecting metabolism. Most 
patients are diagnosed and treated at an early age. There have been very limited reports 
of adults with CAH-associated adrenal myelolipomas. We aimed to analyze two families 
with CAH-associated giant adrenal myelolipomas caused by defects in CYP21A2 and 
CYP17A1 genes. A total of 14 individuals from two unrelated families were identified 
with either CYP21A2 or CYP17A1 mutations. Of note, five patients were found with 
adrenal myelolipomas. Total DNA isolated from the peripheral blood of the two 
probands was screened for potential mutations in the following susceptibility genes of 
CAH: CYP21A2, CYP11B1, CYP17A1, HSD17B3, HSD3B2, ARMC5, and STAR using target 
capture-based deep sequencing; and Sanger sequencing was conducted for the family 
members to detect the potential mutations. The following results were obtained. In 
family 1, molecular genetics sequencing revealed a compound heterozygous mutation 
(c.293-13C>G/c.518T>A, p.I173N) in CYP12A2 in the patient and his brother. In family 2, 
all three female patients with adrenal myelolipomas were found to have a compound 
heterozygous mutation (c.1118A>T, p.H373L/c.1459_1467del9, p.D487_F489del) in 
CYP17A1. To avoid giant CAH-associated adrenal myelolipomas in adults, it is important 
to identify CAH early so that appropriate treatment can be initiated to interrupt the 
chronic adrenal hyperstimulation resulting from increased ACTH. Genetic testing and 
counseling could be useful in CAH.
Introduction
Congenital adrenal hyperplasia (CAH) is one of the 
most severe disorders of metabolism with an overall 
incidence of approximately 1:15,000 worldwide (1). CAH 
encompasses a group of enzymatic deficiencies of cortisol 
synthesis, inherited in an autosomal recessive manner. 
Defective cortisol production results in negative feedback 
at the hypothalamus and pituitary gland, leading to 
excessive secretion of corticotrophin-releasing hormone 
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and adrenocorticotropic hormone (ACTH), respectively. 
Increased levels of ACTH are not only unable to compensate 
for the deficient cortisol synthesis, but their trophic effects 
also produce adrenal gland enlargement (2).
Pathologically, CAH is mainly caused by an inborn error 
of steroid synthesis. Six cytochrome P450 (CYP) enzymes 
including CYP11A1, CYP11B1, CYP11B2, CYP17A1, 
CYP19A1 and CYP21A2 are involved in the synthesis of 
steroid hormones. Although deficiencies of any of these 
enzymes can result in CAH (3), CYP21A2 deficiency 
(21OHD) accounts for up to 95% of all CAH cases (4). 
The CYP21A2 gene is located on 6p21.3, approximately 
30 kb from its pseudogene (CYP21A1P). CYP21A2 
and CYP21A1P share approximately 98% homology 
in their exons and 96% homology in their introns; 
therefore, a high frequency of recombination events 
may occur between the gene and pseudogene, leading 
to varying degrees of CYP21A2 enzymatic deficiency. 
Complete deficiency of CYP21A2 activity leads to both 
glucocorticoid and mineralocorticoid deficiencies, as well 
as severe adrenal-derived androgen excess, resulting in the 
virialized external genitalia of newborn girls. Compared 
to CYP21A2-related disorders, CYP17A1 deficiency is rare. 
The CYP17 gene is located on chromosome 10q24-q25 
and encodes 17α-hydroxylase, which catalyzes the 
17α-hydroxylation of pregnenolone and progesterone and 
the 17,20-cleavage of the corresponding hydroxylated 
steroids (5). CYP17A1 deficiency leads to the impaired 
synthesis of both glucocorticoids and androgen, resulting 
in increased ACTH secretion. Patients present with 
hypertension, hypokalemia and hypogonadism. Both 
46, XY and 46, XX individuals have feminine external 
genitalia and present with amenorrhea and absent 
secondary sexual characteristics during puberty (2).
Adrenal myelolipomas are rare, benign and 
endocrinologically inactive neoplasms composed of 
mature fat tissue and mixed myeloid and erythroid 
tissue (6). They account for approximately 8% of adrenal 
incidentalomas (6). In most cases, adrenal myelolipomas 
are unilateral and rarely exceed 4 cm. However, very 
large and bilateral myelolipomas have been reported, 
especially in the setting of CAH (7). Although these 
tumors are benign, huge masses can produce symptoms 
such as flank pain and abdominal discomfort because 
of rupture, hemorrhage or necrosis (7). Some patients 
with giant adrenal myelolipomas may present with 
even more severe symptoms, including hematuria, 
renovascular hypertension and surgical emergencies such 
as retroperitoneal hemorrhage (8). CAH and Cushing’s 
syndrome are two of the most common causes of adrenal 
myelolipomas (9), and 4% of patients with CAH will 
develop a myelolipoma (10). In this report, we describe 
two adult families with CAH-associated giant adrenal 
myelolipomas secondary to compound heterozygous 
mutations in CYP21A2 and CYP17A1 genes.
Materials and methods
Patients
A total of 15 individuals from two unrelated families were 
sequenced to evaluate whether they carried the mutations 
or not. Among them, 14 individuals were identified with 
either CYP21A2 or CYP17A1 mutations. Of note, five 
patients were found with adrenal myelolipomas. The 
medical records including CT or MRI scan and laboratory 
/pathological examinations, as well as gene sequencing 
results were collected and analyzed. Additional 
information regarding their family history was obtained 
by further interviewing.
Compliance with ethical standards
All procedures involving human participants were 
carried out in accordance with the ethical standards 
of the institutional research committee and with the 
1964 Helsinki Declaration and its later amendments or 
comparable ethical standards. The Daping Hospital of 
Third Military Medical University waived institutional 
review board approval for the study; however, written 
informed consent for the use of medical records and 
related images was obtained from the patients.
Genetic analysis
Total DNA isolated from the peripheral blood of the two 
probands was screened for potential mutations in the 
following susceptibility genes of CAH: CYP21A2, CYP11B1, 
CYP17A1, HSD17B3, HSD3B2, ARMC5 and STAR using 
Target Capture-Based Deep Sequencing (AmCare Genomic 
Laboratory, Guangzhou, Guangdong, China). Briefly, 
the process included fragmentation and construction of 
a genomic DNA, hybridization with custom made probe 
library (Nimblegen, Roche) to capture the genes of interested. 
The sequencing was carried out on NGS platform (HiSeq X 
system; Illumina) with PEx150 read length according to the 
manufactory’s specification. The bioinformatics analysis 
was performed with in-house pipeline to identify rare or 
novel variants with Gnomad, HMGD, ClinVar, dbSNP 
for filtering and computational prediction algorithms, 
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PolyPhen-2, SIFT and MutationTaster, for pathogenesis 
evaluation. After the identification of the variants in the 
proband, family co-segregation analyses were performed 
using Sanger sequencing. The corresponding primers 
were designed by Primer 3.0 and available upon request. 
The final pathogenicity of the variants was estimated 
using the American College of Medical Genetics and 
Genomics guidelines.
Results
Clinical features of the patients
Family 1
A 59-year-old man was referred to our hospital in 
April 2012 with abdominal pain. CT revealed low 
attenuated masses in both adrenal glands (Fig.  1A). On 
admission, his blood pressure was 132/78 mmHg and 
heart rate was 78 beats/min. His physical examination 
was unremarkable, revealing no signs of Cushing’s 
syndrome, hyperaldosteronism or pheochromocytoma. 
Laboratory results demonstrated elevated levels 
of 17-hydroxycorticosteroid (17-OH; 38.5 μmol/24 h, 
normal 8.3–33.2 μmol/24 h) and 17-ketosteroid 
(7-KS; 98.8 μmol/24 h, normal 20.8–76.3 μmol/24 h). 
On April 26, 2012, the patient underwent open bilateral 
adrenalectomies. Intraoperative findings revealed a 1.56 kg 
mass in the left adrenal and a 3.05 kg mass in the right 
adrenal (Fig.  1A, right lower corner). Pathology results 
confirmed the presence of bilateral adrenal myelolipomas 
(Fig. 1C and D). The patient’s older brother had previously 
undergone bilateral adrenalectomies in 1989 at the age of 
50 years for pathology confirmed adrenal myelolipomas. 
Their parents died early with unknown cause. The other 
family members were screened for the disease by CT or 
MRI, as well as hormonal testing. No abnormality was 
found.
Family 2
A 36-year-old woman presented to the affiliated hospital 
of Nanjing University of Traditional Chinese Medical 
with fatigue, headaches and asyndesis (unspeakable) in 
March 2012. She had hypokalemia since childhood and 
hypertension for the past 6  years. On admission, her 
blood pressure was 170/110 mmHg. MRI revealed bilateral 
adrenal masses with a signal intensity similar to that of 
fat, suggesting the presence of adrenal myelolipomas 
(Fig.  1B). Laboratory results showed increased ACTH 
(more than 1250 pg/mL) and decreased cortisol (less 
than 2 μg/dL). In April and November 2012, the patient 
Figure 1
Representative CT scan, MRI scan and 
hematoxylin and eosin (H & E) staining of the 
presenting patients (probands) in each family.  
(A) CT and MRI images showing bilateral adrenal 
masses in the proband for family 1. The adrenals 
removed during surgery are shown in the right 
lower corner. (B) MRI scan showing bilateral 
adrenal masses in the proband for family 2.  
(C and D) H & E staining of the masses in the 
proband for family 1. Magnification: ×100 (C), 
×400 (D).
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underwent left and right adrenalectomies, respectively. 
Intraoperative findings showed a 20 cm × 15 cm × 10 cm 
mass in the left adrenal and another smaller mass in the 
right adrenal.
In June 2012, the patient’s 32-year-old sister was 
referred to the affiliated hospital of Nanjing University of 
Traditional Chinese Medical because of increased fatigue. 
She had presented with fatigue 8 years before, at which 
time she was found to have hypokalemia. CT scan revealed 
a mass in her left adrenal. Laboratory results showed 
increased ACTH (271 pg/mL) and decreased cortisol 
(less than 2 μg/dL). In October 2012, she underwent left 
adrenalectomy, and the pathology results revealed an 
adrenal myelolipoma.
In July 2012, the patient’s 37-year-old sister was 
also referred to the affiliated hospital of Nanjing 
University of Traditional Chinese Medical. She had 
hypertension and hypokalemia for the previous 3 years. 
CT scan revealed bilateral adrenal masses. Laboratory 
results showed increased ACTH (503 pg/mL) and 
decreased cortisol (3.1 μg/dL). In July and December 
2012, she underwent left and right adrenalectomies, 
respectively. Pathology results confirmed the presence 
of adrenal myelolipomas. The other family members 
were asymptomatic on CT or MRI.
Identification of the mutations
Family 1
Considering the positive family history, CAH was 
suspected and genomic analysis was performed using DNA 
isolated from peripheral blood leukocytes. A compound 
heterozygous mutation, consisting of c.293-13C>G and 
c.518T>A, p.I173N, was identified in the CYP12A2 gene 
(Fig.  2A). Sanger sequencing of the CYP12A2 gene was 
conducted in the family members. The brother had the 
same compound heterozygous mutation as the patient. 
The patient’s sister exhibited only the c.518T>A, p.I173N 
mutation. Two of the patient’s daughters had only the 
c.293-13C>G mutation, while another daughter and her 
daughter had only the c.518T>A, p.I173N mutation. 
The daughter of the patient’s brother carried only the 
c.293-13C>G mutation. The family pedigree is shown 
in Fig. 2C.
Family 2
Considering the positive family history, CAH was suspected. 
Genomic sequencing of the patient revealed a compound 
heterozygous mutation, consisting of c.1118A>T, p.H373L, 
and c.1459_1467del9, p.D487_F489del in the CYP17A1 gene 
(Fig. 2B). Sanger sequencing was conducted on the family 
Figure 2
Gene sequencing data and family pedigrees.  
(A and B) Compound heterozygous mutations in 
CYP21A2 gene in family 1 (A) and in CYP17A1 
gene in family 2 (B). (C and D) Pedigrees for 
families 1 (C) and 2 (D). The red arrow indicates 
the proband. ‘?’ represents that the patients were 
not conducted with gene sequencing.
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members, and the patient’s two sisters were found to have 
the same compound heterozygous mutation. Her father and 
asymptomatic brother carried only the c.1118A>T, p.H373L 
mutation, and her mother had only the c.1459_1467del9, 
p.D487_F489del mutation. The family pedigree is 
shown in Fig. 2D.
Discussion
A few cases of CAH-associated adrenal myelolipoma 
have been reported previously with most of them 
caused by 21-OH deficiency. The second most common 
cause was 17-OH deficiency (11). In the current report, 
two patients in family 1 presented with CAH-associated 
giant adrenal myelolipomas secondary to 21-OH 
deficiency caused by a compound heterozygous mutation 
(c.293-13C>G/c.518T>A, p.I173N). Three patients 
in family 2 presented with CAH-associated adrenal 
myelolipomas because of 17-OH deficiency resulting 
from a compound heterozygous mutation (c.1118A>T, 
p.H373L/c.1459_1467del9, p.D487_F489del). All the 
four mutations have been reported to be associated with 
CAH, respectively (12, 13, 14, 15). However, no adrenal 
myelolipoma was found with single mutations. Here, 
we firstly described these two compound heterozygous 
mutations in two unrelated families and found that only 
these compound heterozygous mutations, but not the 
single mutation, in the CYP genes can result in adrenal 
myelolipomas.
A previous study reported that approximately 
65–75% of CAH patients had compound heterozygous 
mutations, and the phenotype correlated with the less 
severely mutated allele (16). However, our results suggest 
that CAH-associated adrenal myelolipomas occurred 
only when compound heterozygous mutations were 
present. In addition, the adrenal myelolipomas caused by 
21-OH deficiency seemed to occur at an older age than 
those caused by 17-OH deficiency, as the individuals in 
family 1 were diagnosed with adrenal myelolipomas at 
approximately 50–60 years of age, whereas those in family 
2 were diagnosed at 30–40 years of age. A previous report 
noted that most adrenal myelolipomas due to 17-OH 
deficiency were unilateral (11). However, the mutations 
(H373L/D487_F489del) in family 2 tended to produce 
bilateral adrenal myelolipomas; the youngest sister 
presented with a tumor that was unilateral, but this may 
have been because of her younger age.
Notably, chronic ACTH hyperstimulation is thought to 
trigger metaplasia in CAH-associated adrenal myelolipomas, 
as more myelolipomas have been described in the setting 
of ACTH-excess CAH (17). Although benign, CAH-
associated adrenal myelolipomas may grow rapidly when 
exposed to chronically elevated ACTH levels for extended 
period (18). Most patients in previous reports were either 
untreated or had stopped taking their CAH medications for 
an extended period (19). The patients in our report were 
all untreated for a prolonged period of time, which led to 
chronic ACTH hyperstimulation and subsequent adrenal 
myelolipomas. Therefore, to avoid giant CAH-associated 
adrenal myelolipomas, it is important to identify CAH 
as early as possible to begin appropriate treatment and, 
thereby, interrupt the chronic adrenal hyperstimulation 
resulting from increased ACTH levels.
Although adrenal myelolipomas were seen in 
both families with different phenotypes. For example, 
hypertension and hypokalemia were observed in only 
family 2. The divergent phenotypes reflected the presence 
of mutations in different genes, CYP21A2 and CYP17A1. 
CYP21A2 deficiency produces reduced aldosterone and 
cortisol and excess testosterone, whereas CYP17A1 
deficiency leads to decreased cortisol and testosterone 
and increased aldosterone, which causes hypertension 
and hypokalemia (2). In the same family, members with 
concurrent mutations in both alleles presented with 
adrenal myelolipomas, whereas individuals with either 
mutation in just one allele did not. This difference in 
tumor occurrence may be due to varying degrees of 
enzymatic deficiency. A previous study found that patients 
with severe mutations causing complete deficiency of 
enzymatic activity presented with severe phenotypes, 
whereas patients with mild mutations exhibited the non-
classical form of CAH (20). In vitro expression analysis 
demonstrated that complete deficiency of 21-hydroxylase 
enzymatic activity could result from multiple mutations 
in the CYP21A2 gene, such as large deletion Δ707-714, 
Q318X and R356W mutations. These mutations could 
cause severe phenotypes, whereas other mutations, 
including P30L (89 C to T), V281L (1685 G to T) and 
P453S (2580 C to T) mutations, may lead to 20–60% 
residual enzymatic activity, which is likely to produce a 
moderate phenotype (20). Furthermore, a previous study 
reported that patients with the classical form of CAH most 
commonly had an IVS2 AS-13 (A/C to G) mutation and 
a large deletion in the CYP21A2 gene (20). These results 
indicate that a strong genotype–phenotype correlation 
exists in CAH. Therefore, individuals with the compound 
mutations described in the current report should be 
treated early to avoid chronic ACTH hyperstimulation 
and actively monitored for adrenal myelolipomas. 
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This highlights the importance of genetic testing and 
counseling in CAH-associated adrenal myelolipomas.
In conclusion, we found that compound heterozygous 
mutations, but not the single mutation, in the CYP 
genes can result in adrenal myelolipomas. Our finding 
also suggests that early diagnosis and timely treatment 
for chronic adrenal hyperstimulation may prevent 
the development of giant CAH-associated adrenal 
myelolipomas. In addition, genetic testing and counseling 
could be valuable means in dealing with CAH.
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